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INTRODUCTION
Treatment of atrial fibrillation (AF) is often demanding because 
of various comorbidities highly prevalent in AF patients. A ho-
listic approach to AF management must include:
 — anticoagulation with regard to the thromboembolic and 
bleeding risk;
 — choosing the rhythm control or rate control strategy;
 — assessment and treatment of cardiovascular (CV) risk 
factors; and
 — treatment of CV and non-CV comorbidities.
Therefore, modern, individually tailored AF treatment 
must be based on current studies and data from clinical trials 
that are summed up in the recommendations or guidelines 
from the various scientific societies. Unfortunately the current 
European AF guidelines do not fully explore the treatment al-
gorithms, especially for specific populations including patients 
with asymptomatic and/or device-detected AF, obstructive 
sleep apnoea (OSA), or chronic kidney disease (CKD) [1, 2]. 
The current review aims to describe the most recent 
data on the management of AF in different clinical scenarios, 
focusing on the anticoagulation strategies and different aspects 
of AF management.
ASYMPTOMATIC AND DEVICE-DETECTED AF
The number of diagnosed AF cases is growing worldwide and 
is likely to double in the forthcoming years [3]. These changes 
are caused by the increasing lifespan of the population and 
improvements in heart rhythm monitoring techniques. Nev-
ertheless, early recognition of AF is not always possible given 
the often ‘silent’ presentation of the arrhythmia. Indeed, 13% 
to 40% of patients with AF do not experience symptoms 
and have been categorised as ‘asymptomatic AF’ [2, 4, 5]. 
One study comparing clinical characteristics of patients with 
first-diagnosed symptomatic and asymptomatic AF showed 
that factors predictive of asymptomatic AF were persistent or 
permanent AF, slower ventricular rate during AF (< 100/min), 
CHA2DS2-VASc score of 0, history of diabetes mellitus, and male 
sex [4]. Other risk factors for asymptomatic AF include older 
age, previous myocardial infarction, and limited physical activity 
[6]. Nevertheless, a recent meta-analysis showed that only male 
sex was an independent risk factor for asymptomatic AF [7].
A large number of asymptomatic AF cases are detected 
due to prolonged heart rhythm monitoring strategies and data 
obtained from implantable electronic cardiac devices (IECDs). 
In patients with ischaemic stroke of unknown aetiology im-
plantable cardiac monitors caused an over 7-fold improve-
ment in the AF detection over 12 months of monitoring, 
while event recorder-detected AF was present in 16.1% of 
patients in the first month, compared to 3.2% in the routinely 
screened group [5, 6]. 
In the population of IECD recipients, the Asymptomatic 
Atrial Fibrillation and Stroke Evaluation in Pacemaker Pa-
tients and the Atrial Fibrillation Reduction Atrial Pacing Trial 
(ASSERT) found that AF (defined as IECD detected episode of 
atrial rate > 190 bpm lasting more than 6 min) was present in 
10% of patients and was associated with a 2.5-fold increase in 
the risk of stroke or systemic thromboembolism [8]. 
In the general population, the risk of all-cause death, 
CV death, stroke, or systemic thromboembolism is at least 
as high or even higher than in symptomatic patients [4, 7]. 
Nevertheless, asymptomatic patients rarely receive oral an-
ticoagulation [9].
Current European guidelines do not address the issue of 
anticoagulation in this population [1, 2], and AF guidelines of 
the Canadian Cardiovascular Society (CCS) recommend anti-
coagulation in patients having > 1 point in the CHADS2 score, 
with silent AF episodes lasting > 24 h and less in case of high 
risk (i.e. recent cryptogenic stroke) [10]. American Heart As-
sociation Guidelines also do not mention anticoagulation in 
asymptomatic patients, but include one recommendation for 
their treatment different from the symptomatic population, 
allowing a lenient rate-control strategy, with resting heart 
rate < 110 bpm for patients with preserved left ventricular 
systolic function [11].
Given the lack of prospective studies assessing the 
benefits and risk from anticoagulation in patients with 
asymptomatic and/or device-detected AF it is reasonable to 
recommend anticoagulation management similar to that for 
patients with symptomatic AF.
Key points
 — Asymptomatic AF is associated with thromboembolic risk 
similar to the general AF population.
 — Anticoagulation in silent and IECD-detected AF is recom-
mended in the same way as in symptomatic patients, 
based on the risk-factor profile.
ATRIAL FIBRILLATION,  
ARTERIAL HYPERTENSION, AND OTHER  
CARDIOVASCULAR RISK FACTORS
Atrial fibrillation is the most common, sustained arrhythmia, 
and arterial hypertension is one of the most prevalent CV risk 
factors [12]. Therefore, AF and arterial hypertension often 
coexist, and hypertension is the most common comorbidity 
in AF patients. Even in relatively young AF patients, arterial 
hypertension is found in over 70% of cases and in recent trials 
such as the RE-LY study, hypertension was diagnosed in 90% 
of patients [13, 14]. 
Hypertension has a role in the development, course, and 
outcomes of AF. The Framingham study showed that the pres-
ence of hypertension increases the odds of developing AF by 
40% to 50% [15]. Untreated or suboptimally treated arterial 
hypertension leads to left ventricular hypertrophy, reduction 
of left ventricular compliance, and an increase in its stiffness 
and filling pressure, with activation of the sympathetic nerv-
ous system and of the renin–angiotensin–aldosterone system. 
www.kardiologiapolska.pl
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These factors lead to enhanced connective tissue deposition 
and atrial fibrosis, which result in electrical, contractile, and 
structural remodelling [16]. The continuum of CV risk factors 
and their relation to AF is shown in Figure 1.
Treatment of hypertension in patients with sinus rhythm 
may lead to the reduction of AF. European hypertension guide-
lines list “prevention of AF” as one of the specific conditions 
in which angiotensin receptor blockers (ARB), angiotensin 
converting enzyme inhibitors (ACEI), beta-blockers, and 
mineralocorticoid receptor antagonists should be preferred 
[17]. At the same time, in the European document there is 
a class IIa recommendation for using ARBs and ACEI in pa-
tients with arterial hypertension for prevention of new-onset 
AF, especially in patients with left ventricular hypertrophy, 
and American guidelines recommend a similar algorithm 
[11]. Also, the guidelines of the Polish Society of Arterial Hy-
pertension recommend using ACEis, ARB, or (in concomitant 
heart failure [HF]) eplerenone for prevention of de novo or 
recurrence of AF [18].
In patients with established AF, guidelines recommend 
other classes of hypotensive agents, mainly due to their heart 
rate reducing properties. The choice of drug for rate control 
depends on lifestyle and concomitant diseases (Fig. 2). In hy-
pertensive patients, the most appropriate drugs reducing heart 
rate in AF include beta-blockers and non-dihydropyridine 
calcium antagonists (Table 1) [1, 11, 18]. 
Figure 1. Association between atrial fibrillation (AF) and arte-
rial hypertension. Modified from [16]; CAD — coronary artery 
disease; LVH — left ventricular hypertrophy
Table 1. Role of hypotensive agents group in the treatment of atrial fibrillation (AF)
Drug groups Additional role in AF patients
Angiotensin converting enzyme inhibitors Prevention of AF development/re-occurrence
Angiotensin receptor blockers Prevention of AF development/re-occurrence
Diuretics None
Beta-blockers Heart rate reduction in rate-control strategy
Dihydropyridine calcium antagonists None
Non-dihydropyridine calcium antagonists Heart rate reduction in rate-control strategy
Mineralocorticoid receptor antagonists (namely, eplerenone) Prevention of AF development/re-occurrence in patients with  
concomitant heart failure
Figure 2. Choice of the appropriate heart rate control drug in atrial fibrillation patients [2].
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Oral anticoagulation treatment in hypertensive AF pa-
tients with no other risk factors is mandatory according to 
the European, Canadian, and Polish guidelines, while the 
American guidelines allow also aspirin or no treatment [3, 10, 
18]. The ‘hypertension’ criterion in the CHA2DS2-VASc score 
refers to history of hypertension or uncontrolled blood pres-
sure. History of hypertension emerges as a stroke risk factor 
given the likely vascular changes associated with prior hyper-
tension (e.g. small vessel disease) that increase the propensity 
to stroke. Also, what is well-controlled hypertension today is 
not necessarily the case over time due to non-compliance 
with drugs, the rise of blood pressure with age, etc. An in-
dividualised approach may be needed in the patient where 
hypertension is the only evident risk factor.
Non-vitamin K oral anticoagulants (NOAC) are a feasible, 
effective treatment option in hypertensive AF patients, char-
acterised by similar efficacy as in normotensive patients [19]. 
Nevertheless, some AF patients require vitamin K antagonists 
(VKA). Decision making between a VKA or NOAC can be 
helped by using the SAMe-TT2R2 score [20]; this simple score 
tries to incorporate the common clinical features associated 
with good anticoagulation control (as reflected by time in 
therapeutic range [TTR]) [21–23], and a SAMe-TT2R2 score of 
0–2 is associated with a good TTR and lower propensity to 
thromboembolism, bleeding, and mortality [24].
Other CV risk factors highly prevalent in AF include 
dyslipidaemia. The guidelines do not address specifically this 
condition in AF patients, but focus on the utility of statins in AF 
patients. Statins are a part of so-called “upstream” therapy in 
AF patients [1]. This kind of treatment is focused on preventing 
onset, re-occurrence, or consequences (including remodel-
ling) of AF. Positive consequences of statin treatment in AF 
include anti-inflammatory and antioxidant actions, reduction 
of endothelial dysfunction and neurohormonal activation, 
altered membrane fluidity, and ion channel conductance 
[25]. Nevertheless, this kind of treatment is recommended 
only in patients with underlying CV disease, HF, or in those 
undergoing coronary artery bypass grafting [2]. Statins may be 
associated with a lower risk of dementia in AF patients [26].
Recent studies show that erectile dysfunctions (a non-clas-
sical CV risk factor) are highly prevalent in AF patients, and are 
associated with a greater thromboembolic risk profile [27, 28]. 
Unfortunately, no data are available on the most appropriate 
mode of treating erectile dysfunction in AF patients.
Key points
 — ACEI and ARB are a valid option for AF prevention in 
hypertensive patients.
 — Beta-blockers and non-dihydropyridine calcium antago-
nists are useful in heart-rate reduction in hypertensive 
AF patients.
 — Patients with AF and arterial hypertension should be 
considered for stroke prevention, oral anticoagulation.
 — Statins are a valid option for AF prevention in patients 
with underlying CV disease, HF, or undergoing coronary 
artery bypass grafting.
ATRIAL FIBRILLATION  
AND CHRONIC KIDNEY DISEASE
Chronic kidney disease is a systemic disease associated with 
alterations in CV, endocrine and nervous system, haema-
topoiesis, and inflammatory response, which promote AF. 
Criteria for CKD are met by approximately 10% to 15% of AF 
patients [1]. The Chronic Renal Insufficiency Cohort (CRIC) 
study, which included patients with estimated glomerular 
filtration rate (eGFR) < 45 mL/min, showed the prevalence 
of AF to be 20.4% [29].
On one hand, CKD is not included in the CHADS2 and 
CHA2DS2-VASc scores routinely used in thromboembolic risk 
assessment. Large studies have shown that CKD with a creati-
nine clearance < 60 mL/min was independently associated 
with elevated stroke risk [30, 31]. Furthermore, stroke risk is 
significantly higher in patients with CKD regardless of baseline 
CHA2DS2-VASc score, and the proportion of high-risk patients 
increases with eGFR category [32, 33]. However, various 
studies have shown that CKD does not independently add to 
stroke prediction in AF [34–36], but this is perhaps unsurpris-
ing since CKD is associated with the component risk factors 
of the CHA2DS2-VASc score.
Chronic kidney disease is also associated with elevated 
bleeding risk, included in the HAS-BLED score. Therefore, 
balancing expected benefit and potential harm of antico-
agulation in AF patients with CKD requires caution. Many 
clinical trials concerning AF treatment put lowered eGFR as 
an exclusion criterion, and results have to be extrapolated 
from the population with normal kidney function. The lack 
of prospective studies concerns mostly dialysis patients and 
those with end-stage kidney disease [37]
Nevertheless, observational cohort studies show that, 
despite increased bleeding risk, anticoagulation in patients 
with CKD, AF, and high thromboembolic risk is associated 
with a net clinical benefit, represented by reduction in the 
risk of all-cause death, CV death, and composite end-point 
of fatal stroke/fatal bleeding [38].
No specific recommendations are available on the an-
ticoagulation and choosing between NOAC and VKA in AF 
patients with mildly depressed renal function. All oral antico-
agulants are metabolised in kidney (but to different extents), so 
they require dose modification according to kidney function 
(Table 2) [39]. Warfarin is metabolised in the kidney in 92% 
of the dose. This might be one of the reasons why warfarin 
causes a gradual decrease in kidney function [40]. Other 
reasons include renal microbleeds, and warfarin-induced 
calcification and apoptosis of renal cells [41, 42].  
Limited data on the unfavourable effect on kidney function 
are available for NOAC. One interesting study reported that the 
www.kardiologiapolska.pl
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rate of renal function decline was lower in dabigatran-treated 
patients compared to those treated with warfarin, in the RELY 
trial [40]. This, along with lower risk of bleeding compared to 
warfarin, is a reason for recommending NOAC over warfarin 
for patients with mild to moderate CKD. Of course, dose ad-
justment is required according to kidney function, and NOAC 
treatment in patients with creatinine clearance < 15 mL/min 
(< 30 mL/min for dabigatran) in not recommended.
Key points
 — AF patients with CKD have elevated thromboembolic 
and bleeding risk.
 — NOACs are a valid anticoagulation option in this group of 
patients, as long as prescription label guidance is followed.
ATRIAL FIBRILLATION AND HEART FAILURE
Heart failure is one of the CV diseases associated with the 
worst prognosis and the highest mortality rate. It is often as-
sociated with heart muscle remodelling that causes myocar-
dial stretch and fibrosis that promotes arrhythmia, including 
AF. The prevalence of AF in HF patients depends on the HF 
severity. In asymptomatic patients AF is found in 6% of cases, 
while it is between 15% and 30% in patients with higher New 
York Heart Association classes [43, 44].  
During the progressive course of HF, methods focused on 
preserving sinus rhythm are less effective, and AF transforms 
to persistent/permanent form in most cases. Therefore, a rate 
control strategy is widely used in HF patients. Rapid ventricular 
rhythm is associated with worse prognosis. An increase in the 
heart rate by 10 bpm causes an increase of over 25% in the risk 
of all-cause death, CV death, or HF hospitalisation [45]. Euro-
pean and American guidelines recommend beta-blockers and 
digoxin for heart rate control in AF patients with HF [1, 11]. 
A recent meta-analysis compared the effects of digoxin 
on death from any cause in AF and chronic HF patients, 
and found that in AF patients with HF, who were treated 
with digoxin, there was an overall 21% increase in the risk 
of death from any cause compared with patients who were 
not receiving this treatment [46]. Therefore, it is probably 
reasonable to recommend treatment with beta-blockers in 
patients with AF and HF for heart rhythm reduction. However, 
a study by Kotecha et al. [47] showed that in patients with 
HF and AF treatment with beta-blockers did not led to a sig-
nificant reduction in mortality observed in a population with 
sinus rhythm. Therefore, beta-blockers should not be used 
preferentially over other rate-control medications and should 
not be regarded as standard therapy to improve prognosis in 
patients with concomitant HF and AF.
As with anticoagulation, HF is an independent risk factor 
for thromboembolism, which is included in the most popular 
risk scores. In the first year from HF occurrence, 2% of patients 
are afflicted with stroke [48]. In the settings of concomitant 
AF and HF, blood stasis is caused by blood flow stasis in the 
atria and ventricles and worsening patient prognosis. Oral 
anticoagulation is essential in HF patients with AF. One 
recent meta-analysis showed that in this group of patients 
standard-dose NOAC regimens have a better efficacy and 
safety profile than warfarin, while low-dose regimens are 
similarly effective and safe as warfarin, and therefore should 
be preferred [49].
Key points
 — HF is one of the most important thromboembolic risk 
factors in AF patients.
 — In light of recent data, beta-blockers should be recom-
mended for rate-control in AF, and digoxin should be 
prescribed with caution.
 — The majority of patients with HF require oral anticoagula-
tion, and (full-dose) NOACs seem to be a more efficient 
and safe treatment option.
Table 2. Pharmacokinetics of oral anticoagulants depending on kidney function; estimated drug half lives and effect on area 
under the curve non-vitamin K oral anticoagulants plasma concentrations in different chronic kidney disease (CKD) stages
dabigatran apixaban edoxaban rivaroxaban
Percentage elimination in kidney 80% 27% 50% 35%
Creatinine clearance > 80 mL/min 12–17 h 12 h 10–14 h 5–9 h young
11–13 h elderly
Creatinine clearance 50–80 mL/min
I–II stages CKD
~17 h (+50%) ~14.6 h (+16%) ~8.6 h (+32%) ~8.7 h (+44%)
Creatinine clearance 30–50 mL/min
III stage CKD
~19 h (+320%) ~17.6 h (+29%) ~9.4 h (+74%) ~9 h (+52%)
Creatinine clearance 15–30 mL/min
IV stage CKD
~28 h (+530%) ~17.3 h (+44%) ~16.9 h (+72%) ~9.5 h (+64%)
Creatinine clearance ≤ 15 mL/min
V stage CKD
No data – (+36%) – (+93%) – (+70%)
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ATRIAL FIBRILLATION  
AND OBSTRUCTIVE SLEEP APNOEA
Obstructive sleep apnoea is a disease highly prevalent in 
patients with CV disease, including patients with AF [50]. 
Recent studies concerning relatively young populations of 
AF patients show that OSA is found in approximately 40% 
of cases [51].
Obstructive sleep apnoea is independently associated 
with a risk of myocardial infarction, stroke, and death [52]. 
In AF patients it worsens the outcomes of cardioversion and 
ablation procedures [53, 54]. Whenever possible, upstream 
treatment of OSA should be considered prior to ablation or 
cardioversion. For example, continuous positive airway pres-
sure (CPAP) therapy may be a feasible option for AF recurrence 
risk reduction and for improving the patient’s general CV risk 
profile [52]. One recent meta-analysis showed that CPAP treat-
ment is associated with a 42% decrease in the risk of AF [55].
Obstructive sleep apnoea is independently associated 
with higher thromboembolic risk, translated also to alterations 
in biomarkers [56]. It is advised to screen patients for OSA to 
improve identification of high stroke risk patients and choosing 
appropriate thromboprophylaxis [57].
Key points
 — OSA is underdiagnosed and undertreated in the general 
population and in AF patients.
 — OSA is associated with elevated thromboembolic risk in 
AF patients.
 — OSA worsens the outcomes of rhythm control strategy 
in AF.
 — Treatment of OSA may lower the thromboembolic risk and 
improve outcomes of procedures such as AF cardioversion 
and ablation.
CONCLUSIONS
Treatment of AF in the setting of underlying conditions is 
often difficult and demanding. Modern management strate-
gies in specific patient groups with AF require knowledge on 
the recommendations included in guidelines from different 
scientific societies as well as the results of more recent studies. 
Conflict of interest: none declared
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